Infectious Diseases | Novartis

Media Release
Aug 28, 2023
Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio
Media Release
Jan 24, 2023
Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio
Media Release
Nov 07, 2022
Sandoz announces further investment in key manufacturing facility in Austria, to support increased global demand for essential antibiotics
Media Release
Jun 23, 2022
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
Story
Jun 23, 2022
Renewing our commitment to neglected tropical disease and malaria elimination
Story
Apr 19, 2022
Staying one step ahead of the malaria parasite
Story
Apr 07, 2022
Tackling the health toll of climate change
Media Release
Oct 28, 2020
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19
Media Release
Dec 14, 2020
Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19
Media Release
Mar 04, 2021
Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
Media Release
Apr 02, 2020
Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program
Media Release
Apr 20, 2020
Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients